Houston named the No.1 emerging city for biopharma in inaugural report

Biopharma Leader

The report considered patents, NIH funding, lab space, venture capital investments and the number of jobs. Photo via Pexels

Houston is ranked No.1 on the first-ever Next 10 U.S. Biopharma Clusters report published by Genetic Engineering & Biotechnology News (GEN).

The report, which ranks the best emerging hubs for life science activities, considered patents, NIH funding, lab space, venture capital investments, and the number of jobs in regions in cities, states and “clusters” across the U.S. GEN touts Houston as the top city for the biopharma industry due to a surge in funding, job creation, medical innovations and startup success.

Here’s how Houston ranked in the report’s different categories;

  • No. 1 for NIH funding with 2,262 awards totaling more than $1.25 billion
  • No. 2 for emerging regions for jobs, with 28,000 jobs
  • No. 2 for lab space, with roughly 8 million square feet in the market
  • No. 6 for patents, with 2,760 patent families

According to BioHouston chairman Jeff Wade, Houston secured half a billion dollars in venture capital funding in 2025 and 2026 to date.

The report called out major biopharm news out of Houston in the last few months, including Bristol Myers Squibb selecting Houston for its $1 billion, 600,000-square-foot manufacturing site and Eli Lily selecting Houston for its $6.5 billion, 236-acre manufacturing site. Both facilities will be located within Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston.

Houston startups like CrossBridge Bio and Duracyte were also mentioned in the report. CrossBridge, which develops antibody-drug conjugates for cancer, was acquired by Eli Lily in April for $300 million. Duracyte, a “living pharmacy” company, was launched out of Rice University’s biotech venture studio RBL LLC this spring and is backed by up to a $45 million Advanced Research Projects Agency for Health (ARPA-H) award.

The startup is working to commercialize its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR) technology, a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time.

“There’s a lot of great talent, but the unique advantage that we have is we are able to benefit from a lot of unique clinical infrastructure and clinician insights,” Omid Veiseh, Duracyte co-founder and managing partner of RBL LLC, told GEN. “There are a lot of clinicians here who are eager to partner on investigator-initiated trials.”

The report also touted Houston’s Texas Medical Center, home to the University of Texas MD Anderson Cancer Center and Baylor College of Medicine, and international partnerships like the recently expanded TMC Korea BioBridge.

Other cities to make the list include:

  • No. 2 Minneapolis-St. Paul
  • No. 3 Denver-Boulder
  • No. 4 St. Louis
  • No. 5 Dallas-Fort Worth

States to make the list include:

  • No. 1 Ohio (including Cincinnati, Cleveland, and Columbus)
  • No. 2 Indiana (including Indianapolis)
  • No. 3 Florida (including Jacksonville and Miami-Fort Lauderdale)
  • No. 4 Georgia (including Atlanta and Augusta)
  • No. 5 Wisconsin (including Madison and Kenosha)

Regional state clusters to watch include:

  • Phoenix
  • Pittsburgh
  • Greater Richmond, Virginia
  • South Carolina
  • Utah

See the full report here.

From Your Site Articles
Tianhong Cui, a lab-on-a-chip and microelectromechanical expert, will join the University of Houston. Photo courtesy University of Minnesota Twin Cities

Houston lands $14M in latest CPRIT grants to advance cancer, lab-on-chip research

cancer funding

Thanks to a $4 million grant from the Cancer Prevention and Research Institute of Texas, the University of Houston has recruited a top-tier researcher developing AI-powered lab-on-a-chip technology for early cancer detection.

Tianhong Cui, a professor of mechanical engineering at the University of Minnesota Twin Cities and an adjunct professor of physiology and biomedical engineering at the Mayo Clinic, specializes in microelectromechanical systems and advanced manufacturing at microscale and nanoscale levels. In addition to lab-on-a-chip systems, Cui focuses on biosensors and water sensors.

Lab-on-a-chip devices deliver big results in a tiny package

The CPRIT grant supports Cui’s development of a microscale lab-on-a-chip system for early cancer detection and post-therapy monitoring.

“Lab-on-a-chip technology crams an entire lab’s worth of functions into a tiny device roughly the size of a USB stick,” according to Built In.

Common uses for the technology include medical diagnostics, point-of-care testing, and environmental monitoring.

Lab-on-a-chip work being carried out at UH and elsewhere in Houston promises to revolutionize cancer detection and treatment. For instance, Houston biotech company iBiochips, a spinout from the Houston Methodist Research Institute, makes lab-on-a-chip devices that bolster cancer detection and therapy.

Four local organizations gain $10 million in CPRIT grants

Four other Houston-area organizations received an additional $10 million in grants in CPRIT’s latest round of funding:

  • University of Texas MD Anderson Cancer Center received two $2 million grants to recruit researchers Zheqi Li of Harvard University’s Dana-Farber Cancer Institute and Nikolaos Koundouros of Weill Cornell Medicine.
  • Rice University received one $2 million grant to recruit researcher Maria Akoppyan, formerly of the University of Southern California.
  • UT Medical Branch at Galveston received one $2 million grant to recruit researcher Cristina Santarossa of Johns Hopkins University.
  • Houston-based biopharma company Pulmotect received one $2 million grant to support better outcomes for cancer patients by activating immunity in the lungs as a first line of defense against germs.

The funding was part of $35 million in new CPRIT grants for institutions and companies across Texas approved at the organization's most recent meeting. To date, CPRIT has awarded more than $4.2 billion in grants.

“These awards support research across the cancer continuum from prevention to new classes of therapeutics,” said Dr. Scott Hiebert, chief scientific officer of CPRIT, said in a news release. “The work of these investigators will impact the lives of Texans across the state.”

A rendering of the $5 billion University of Texas Dell Medical Center in Austin. Image via utexas.edu

$5B MD Anderson-anchored Austin medical center to break ground this fall

moving forward

Construction on the $1 billion first phase of the AI-native University of Texas Dell Medical Center in Austin—which will feature a hospital operated by Houston’s UT MD Anderson Cancer Center—is set to start this fall.

The UT System Board of Regents approved funding for first-phase construction on Aug. 12.

The medical center—now expected to cost $5 billion, up from the initial $2.9 billion estimate—will span about 2.5 million square feet. It will include 300 to 500 patient beds, outpatient facilities, an emergency department and specialized care for cancer patients.

MD Anderson will bring its world-renowned oncology programs to the center’s integrated health care model, Dr. Claudia Lucchinetti, senior vice president of medical affairs at UT Austin and dean of the university’s Dell Medical School, tells Health Leaders.

Earlier this year, Austin tech billionaire Michael Dell and his wife, Susan, pledged $750 million for development of the medical center. The medical center, scheduled for completion in December 2030, will be a cornerstone of the new 300-acre UT Dell Campus for Advanced Research, a medical education and research hub.

“Through this new campus and medical center, Texas will lead America in health care innovation,” Gov. Greg Abbott said when the research campus was announced in April. “The next generation of medical breakthroughs will take place in Central Texas.”

The medical center will fold AI tools and other technology into the infrastructure, rather than having them added after it’s built. Among other capabilities, the technology will monitor real-time medical data, automate data entry, and help health care professionals quickly predict and identify risks to patients, according to Health Leaders.

“We are not just building a new medical center,” Lucchinetti says. “We are building a fundamentally new model of health. It’s not just a new facility. It’s not just a new collaboration. It is a convergence of capabilities that rarely come together at the same time.”

Houston Methodist has recruited Dr. Daniela Matei, an expert in ovarian and endometrial cancer, to lead the Dr. Mary and Ron Neal Cancer Center. Photo courtesy Houston Methodist.

U.S. News declares Houston hospital No. 1 in Texas for the 15th year

Top of the Chart

Houston Methodist Hospital and over a dozen more Houston-area hospitals have earned bragging rights in U.S. News & World Report's newly released rankings of the Best Hospitals for 2026-2027.

Every year, U.S. News annually evaluates nearly 4,500 U.S. hospitals to determine which meet the publication's rigorous standards and offer the best care for patients across 14 adult specialties and 23 procedures and conditions. New to this year's batch of rankings, U.S. News introduced regional rankings in cancer; cardiology; heart and vascular surgery; orthopedics; and rehabilitation.

Houston Methodist Hospital was the only Texas institution named on U.S. News' Best Hospitals Honor Roll, a prestigious list of the 20 best medical centers in the country. Houston Methodist also reigns as Texas' best hospital for the 15th consecutive year.

The hospital also shines among the nation’s best in 10 specialties:

  • No. 5 – Gastroenterology and GI Surgery
  • No. 7 – Obstetrics and Gynecology
  • No. 10 – Cardiology, Heart, and Vascular Surgery
  • No. 11 – Pulmonology and Lung Surgery
  • No. 13 – Neurology and Neurosurgery
  • No. 19 – Cancer
  • No. 21 – Orthopedics
  • No. 23 – Diabetes and Endocrinology
  • No. 24 – Geriatrics
  • No. 43 – Urology
Houston Methodist also earned high performing distinctions across one regional specialty (Rehabilitation) and 21 procedures and conditions.

"This recognition reflects the remarkable dedication of our physicians and employees and their tireless focus on delivering unparalleled care to our patients," said Houston Methodist president and CEO Marc L. Boom, M.D. in a press release. "While we are honored by this recognition, its true significance lies in what it represents — an unwavering commitment to putting patients first."

Elsewhere in Houston, The University of Texas MD Anderson Cancer Center ranked as the No. 1 best cancer hospital in the nation for the 12th year in a row.

"This ranking is a tremendous honor, and it reflects our unwavering commitment to continue making progress in our mission to end cancer," said UT MD Anderson president Peter WT Pisters, M.D. "We are deeply grateful to everyone who made this recognition possible: our faculty and staff, volunteers, donors, and the patients and families we are honored to serve."

MD Anderson also earned national rankings in two specialties — Urology (No. 6) and Gastroenterology and GI Surgery (No. 16) — and it received high performing distinctions in six procedures and conditions: Colon Cancer Surgery; Ear, Nose, and Throat Surgery; Gynecological Cancer Surgery; Leukemia, Lymphoma, and Myeloma Treatment; Lung Cancer Surgery; and Prostate Cancer Surgery.

The additional Houston hospitals that ranked among the best in Texas for 2026-2027 are:

  • No. 3 – Houston Methodist Sugar Land Hospital (tied with Baylor University Medical Center Dallas)
  • No. 5 – Baylor St. Luke's Medical Center, Houston
  • No. 6 – Memorial Hermann Hospital, Houston
  • No. 7 – Houston Methodist The Woodlands Hospital
  • No. 10 – Memorial Hermann Greater Heights Hospital (tied with St. David's Medical Center, Austin)
  • No. 14 – Houston Methodist Baytown Hospital
  • No. 15 – Memorial Hermann Memorial City Medical Center, Houston
  • No. 21 – Houston Methodist Clear Lake Hospital, Nassau Bay; St. Luke's Health-The Woodlands Hospital; University of Texas Medical Branch, Galveston (also tied with six more Texas hospitals)
  • No. 30 – Memorial Hermann Sugar Land Hospital (tied with five other Texas hospitals)
  • No. 36 – HCA Houston Healthcare Kingwood (tied with Parkland Health-Dallas)
---

This article originally appeared on CultureMap.com.

Rice University researchers reported promising results from the first human trial of an implantable cancer immunotherapy designed to fight tumors while reducing side effects. Photo via Unsplash

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

A rendering of the multibillion-dollar Austin medical center. Courtesy rendering

New UT Austin med center, anchored by MD Anderson, gets historic gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

---

This article originally appeared on CultureMap. A previous version stated the gift was $1 billion; the Dell's total gift to UT is $1 billion, with this donation at $750 million.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Major Texas-based airlines ground humanoid robots as passengers

In The Air

Two major airlines based in Texas are drawing a hard line between human and humanoid: American Airlines and Southwest Airlines won’t permit human-like or animal-like robots to board flights as passengers.

Fort Worth-based American and Dallas-based Southwest recently adopted bans on robotic passengers after two incidents in which human-like robots joined flesh-and-blood passengers on Southwest flights.

In May, Aaron Mehdizadeh, owner of The Robot Studio rental company in Dallas, was heading from Las Vegas to Dallas Love Field with 3.5-foot-tall Stewie, according to CBS News Texas. Rather than shipping Stewie as cargo, Mehdizadeh bought the robot its own seat using a type of ticket often purchased for fragile items such as wedding dresses and equipment.

But because Stewie was technically a carry-on item, the robot wasn’t supposed to occupy a seat, according to eWeek. Crew members wound up disconnecting Stewie’s battery and relocating the robot to a window seat before takeoff.

Mehdizadeh pushed back on Southwest’s stance regarding the battery, telling CBS News Texas that Stewie’s power supply is a standard battery that’s similar to one for a laptop.

Stewie isn’t the only robot making mischief in the skies. In May, a 70-pound, human-like robot named Bebop caused a stir on a Southwest flight from Oakland, California, to San Diego.

The robot prompted a nearly one-hour flight delay after crew members realized it violated restrictions on large carry-ons and raised concerns about the battery, San Francisco TV station KGO reported. Dallas-based Elite Event Robotics owns Bebop.

Southwest seized Bebop’s lithium-ion battery, but the airline did let Bebop take the San Diego-bound flight.

Southwest’s new robot policy prohibits human-like or animal-like robots from riding in an airplane cabin or as checked baggage, no matter their size or purpose. All other robots, including toys, must fit in a carry-on size bag and comply with battery restrictions, the airline says.

In a statement sent to CultureMap, a Southwest spokeswoman says the airline “has taken a strong stance on this issue and has led the U.S. airline industry with our battery policy.”

“The robot policy is a further evolution of a [safety] journey we have been on for several months. This move was not in response to any single incident,” the spokeswoman adds. “To eliminate confusion, the policy applies to all similar devices, regardless of size.”

Lithium-ion batteries can overheat, catch on fire, or explode on airplanes.

American’s new robot policy, which took effect Monday, August 17, is similar to Southwest’s. The policy prohibits human-like and animal-like robots from sitting in a purchased seat, being stored in an overhead bin or traveling as checked baggage. The ban applies to U.S., international, and regional flights.

“While there have been no known events involving this type of robot on any American flight, this policy was developed following a comprehensive review of safety risks associated with these devices, including the large lithium-ion batteries that power them,” the airline said in an internal memo obtained by the View From the Wing travel blog.

American gate agents have been told not to allow a passenger accompanied by a robot to board a plane or to let a robot travel as a checked item, the memo say.

If a robot is discovered after check-in, American employees are supposed to follow the Federal Aviation Administration’s “undeclared dangerous goods” procedures. These procedures cover hazardous shipments like lithium-ion batteries, explosives, flammable liquids, and compressed gases that lack required warning labels or shipping documents.

---

This article originally appeared on CultureMap.com.

Texas A&M, UH rise in global rankings of universities attracting the most attention

visibility report

Houston and Texas universities had a strong showing on the 2026-27 Global University Visibility (GUV) Rankings compiled by D.C.-based higher ed market research firm American Caldwell.

Texas A&M ranked No. 6 on the list—the top rank of any Texas university. Meanwhile, the University of Houston ranked No. 52, a 15-spot jump from its previous ranking.

The GUV rankings rate colleges that garner the most global attention via news coverage, social media influence, website traffic, YouTube views, and general public interest. GUV evaluated over 1,200 universities across 193 United Nations-recognized countries.

Texas A&M, with its No. 6 global ranking, also claimed the No. 5 spot among U.S. institutions. The university climbed 21 spots from its previous rank.

“News mentions were a driver of Texas A&M’s movement in this year’s rankings, and earned media remains one of the strongest signals of relevance,” Tim Doty, associate vice president for earned media at Texas A&M, said in a news release. “Much of that visibility begins with our faculty and research experts, whose work helps explain, solve and give context to issues people care about. When Texas A&M experts appear in news stories about research, discovery, national security, agriculture, health, engineering, service and the future of Texas, audiences see the university not only as large or well known, but as useful, relevant and necessary to the conversations shaping our state and country.”

In the “Public Interest” category, UH also claimed a top 10 global ranking at No.6. UH touts its overall GUV rankings success to Guggenheim Fellowships, MacArthur “Genius” grants, National Academy membership, studies like researchers breaking the superconductivity temperature record, and success on the football field and basketball courts.

“Across the board, there is no question that the University of Houston is a brand on the rise,” Shawn Lindsey, interim vice president for marketing and communications, said in a news release. “People are seeing our story, hearing about the amazing things happening at UH and actively seeking us out to learn more. We are seeing it in record-high student applications, we are seeing increases in trademark licensing revenue, our faculty are earning global accolades. It’s an exciting time to be a Houston Cougar.”

Other Texas institutions to make the top 250 on the list include:

  • No. 22 The University of Texas at Austin
  • No. 104 University of Texas at Dallas
  • No. 159 Texas Tech University
  • No. 178 Rice University
  • No. 191 University of North Texas
  • No. 248 Texas State University

For the fourth year in a row, Harvard University secured the top spot on the list, followed by MIT, Stanford University and Purdue University. The University of Oxford was the top non-U.S. institution at No. 5.

See the full list here.

Astrodome group seeks new ideas for future of historic Houston landmark

8th Wonder News

The Astrodome may have once been touted as the Eighth Wonder of the World, but its current condition remains one of Houston's most famous follies. In an effort to find a better use for the iconic building, The Astrodome Conservancy has released a Request for Information (RFI), inviting proposals from interested parties on how the historic landmark might be used in the future. Respondents have until September 8 to submit their responses at the official conservancy site.

“This RFI is an opportunity for the market to help shape a shared vision for the Astrodome,” said Beth Wiedower Jackson, executive director of the Astrodome Conservancy, in a release. “We are looking to gather creative, feasible, and financially viable ideas that reflect both the significance of the Astrodome and its potential as a catalyst for future development.”

When the Astrodome opened in 1965, it was a marvel of engineering and the world's first air-conditioned, multi-purpose domed sports stadium. It remained an iconic part of Houston until changing trends in sports sent the Astros and the Houston Livestock Show and Rodeo to newer stadiums with modern amenities. After the 2003 rodeo, the dome was closed, except for a brief use as an evacuation shelter for Hurricane Katrina.

A decades-long fight over what to do with the Astrodome followed that closure. The City of Houston condemned the building for various code violations in 2009. Fully renovating it would cost over $700 million — a tall order for taxpayers. Demolishing it would be far cheaper (around $55 million), but its status on the National Register of Historic Places makes that virtually impossible. Meanwhile, Harris County pays hundreds of thousands of dollars a year to maintain the building.

Proposals for the space have run the gamut. In 2024, the Astrodome Conservancy proposed Vision: Astrodome, which would transform the building into an indoor mall and event space. That still appears to be the foundation of the plan according to the RFI.

The RFI is seeking private investment to partner with the Harris County property. Proposals are merely for planning purposes and will not automatically lead to contracts for development. Section 2.3 states that participants in the new mixed-use space will "require back-of-house infrastructure improvements to support reliable operations at scale," likely meaning that the plan is to fund some of the much-needed renovations via tenants. However, the RFI points out that participants in the revitalized Astrodome will also be eligible for historic space preservation tax credits.

While Vision: Astrodome seems committed to using the stadium as a public space for the entertainment of Houstonians, the RFI is clear other options are on the table.

The Astrodome possibly being used to house a data center is specifically mentioned, though the RFI mandates such a proposal would need to be very upfront about the infrastructure demands and continuing operating costs of such a project. Public backlash against data centers led to Governor Greg Abbott ordering a pause on grid connections to them pending further review.

"The Astrodome presents a unique opportunity for adaptive reuse and redevelopment that honors its legacy while positioning it for long-term community and economic impact," said the conservancy in the release announcing the RFI.

View All Listings